CAMPBELL, Calif.--(BUSINESS WIRE)--Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, today announced a newly expanded, multi-year agreement with global biopharmaceutical leader Pfizer to help expedite clinical research.

加利福尼亚州坎贝尔市（商业新闻短讯）--Saama是一家基于人工智能的解决方案提供商，可加速临床开发和商业化，今天宣布与全球生物制药领导者辉瑞公司（Pfizer）达成一项新的扩展多年协议，以帮助加快临床研究。

The agreement represents the expansion of a strategic relationship that began in 2020 when Saama and Pfizer entered into a partnership to automate Pfizer’s data review processes with artificial intelligence (AI). The result of that initial collaboration was Smart Data Quality (SDQ), which significantly cut down the time to database lock.

该协议代表了战略关系的扩展，该关系始于2020年，当时萨玛和辉瑞结成伙伴关系，通过人工智能（AI）自动化辉瑞的数据审查流程。最初合作的结果是智能数据质量（SDQ），这大大缩短了数据库锁定的时间。

With this new agreement, Pfizer will continue to scale SDQ to help streamline and accelerate its data review processes across its broader portfolio of global studies..

根据这项新协议，辉瑞将继续扩大SDQ的规模，以帮助简化和加速其更广泛的全球研究组合中的数据审查过程。。

“Our initial collaboration with Pfizer for its COVID-19 vaccine demonstrated the unprecedented power of our AI-enabled technology platform to improve and accelerate the clinical trial process, and ultimately, its ability to help bring treatments to patients faster,” said Lisa Moneymaker, Chief Technology Officer and Chief Product Officer, Saama.

Saama首席技术官兼首席产品官丽莎·莫尼梅克（LisaMoneymaker）表示：“我们与辉瑞（Pfizer）就新型冠状病毒肺炎（COVID-19）疫苗进行的初步合作表明，我们的人工智能技术平台具有前所未有的力量，可以改进和加速临床试验过程，并最终帮助更快地为患者提供治疗。”。

“The opportunity to now scale across more of the Pfizer portfolio underscores the evidence-based potential of Saama’s one-of-a-kind platform to fundamentally change the way drug development is done to benefit more people around the world.”.

“现在有机会在辉瑞的更多投资组合中扩大规模，突显了萨玛独一无二的平台的循证潜力，可以从根本上改变药物开发的方式，使全世界更多的人受益。”。

“Building a sustainable framework to accelerate analysis and reporting for clinical trials is fundamental to speeding up the development of breakthrough medicines,” said Demetris Zambas, Vice President and Global Head Data Monitoring and Management, Pfizer. “We look forward to expanding our strategic partnership with Saama across our global portfolio, leveraging their cutting-edge, AI-based technologies to reduce the time and effort required for data review and reconciliation, and to improve the quality and consistency of data across routine and complex clinical studies alike.”.

辉瑞公司副总裁兼全球数据监测和管理负责人德米特里斯·赞巴斯（DemetrisZambas）表示：“建立一个可持续的框架来加速临床试验的分析和报告，对于加速突破性药物的开发至关重要。”。“我们期待着在我们的全球投资组合中扩大与萨玛的战略合作伙伴关系，利用他们基于人工智能的尖端技术，减少数据审查和核对所需的时间和精力，并提高常规和复杂临床研究中数据的质量和一致性。”。

Not limited to SDQ, the new agreement expands the existing relationship to help Pfizer to accelerate regulatory submissions across its portfolio using Saama’s new advanced Biometrics Research and Analysis Information Network. Pfizer will now have the potential to reduce regulatory submission timelines across its global portfolio, as this next-generation solution streamlines statistical programming and biostatistics workflows, digitizes study specifications, and generates submission-ready tables, listings, and figures (TLF) artifacts.

新协议不仅限于SDQ，还扩展了现有关系，以帮助辉瑞利用萨玛新的先进生物特征研究和分析信息网络加速其投资组合的监管提交。辉瑞现在有可能缩短其全球投资组合的监管提交时间表，由于这种新一代解决方案简化了统计编程和生物统计学工作流程，数字化了研究规范，并生成了可提交的表格，列表和数字（TLF）工件。

It will also set the stage for continuing automation and innovation to further accelerate future trial submissions..

它还将为继续自动化和创新奠定基础，以进一步加速未来的试用提交。。

Saama’s solutions use the industry’s most advanced technology and AI capabilities to give study teams the power to manage the high volume and variety of today’s clinical trial data.

萨玛的解决方案利用业界最先进的技术和人工智能能力，为研究团队提供管理当今大量多样临床试验数据的能力。

Throughout studies, data are centralized and standardized from multiple sources to enable streamlined medical review processes, improve patient safety oversight, predict participant behavior, accelerate clinical signal discovery, and more.

在整个研究过程中，数据从多个来源集中和标准化，以简化医疗审查流程，改善患者安全监督，预测参与者行为，加速临床信号发现等。

The Saama platform of AI-enabled SaaS products and solutions supports the full spectrum of clinical development. To learn more about the Saama platform and its custom solutions and services or to schedule a personalized demonstration, visit saama.com.

支持人工智能的SaaS产品和解决方案的Saama平台支持全方位的临床开发。要了解有关Saama平台及其定制解决方案和服务的更多信息，或安排个性化演示，请访问Saama.com。

We also invite you to meet us at booth 813 at the SCOPE Summit from February 11-14 in Orlando, Florida.

我们还邀请您在2月11日至14日于佛罗里达州奥兰多举行的SCOPE峰会813号展位与我们会面。

About Saama

关于Saama

Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives.

Saama开发了生命科学解决方案，可以加速向患者提供治疗。凭借创新的人工智能技术，萨玛将突破性的智能应用于临床和商业运营。Saama平台为临床试验提供了动力，该试验产生了世界上第一种新型冠状病毒肺炎疫苗。萨玛公司总部位于加利福尼亚州坎贝尔，员工遍布全球，致力于帮助客户挽救和改善生活。

Discover more at saama.com..

更多信息请访问saama.com。。